{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:42:15Z","timestamp":1789688535402,"version":"4.0.1"},"reference-count":313,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide and pomalidomide are antitumor compounds that have direct tumoricidal activity and indirect effects mediated by multiple types of immune cells in the tumor microenvironment (TME). IMiDs have shown remarkable therapeutic efficacy in a set of B-cell neoplasms including multiple myeloma, B-cell lymphomas and chronic lymphocytic leukemia. More recently, the advent of immunotherapy has revolutionized the treatment of these B-cell neoplasms. However, the success of immunotherapy is restrained by immunosuppressive signals and dysfunctional immune cells in the TME. Due to the pleiotropic immunobiological properties, IMiDs have shown to generate synergetic effects in preclinical models when combined with monoclonal antibodies, immune checkpoint inhibitors or CAR-T cell therapy, some of which were successfully translated to the clinic and lead to improved responses for both first-line and relapsed\/refractory settings. Mechanistically, despite cereblon (CRBN), an E3 ubiquitin ligase, is considered as considered as the major molecular target responsible for the antineoplastic activities of IMiDs, the exact mechanisms of action for IMiDs-based TME re-education remain largely unknown. This review presents an overview of IMiDs in regulation of immune cell function and their utilization in potentiating efficacy of immunotherapies across multiple types of B-cell neoplasms.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1017990","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T05:47:24Z","timestamp":1665553644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms"],"prefix":"10.3389","volume":"13","author":[{"given":"Hao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.3390\/cancers13092266","article-title":"Advances and perspectives in the treatment of b-cell malignancies","volume":"13","author":"Cuenca","year":"2021","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for b cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature b-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in b-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"H\u00f6pken","year":"2019","journal-title":"Trends Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-019-0992-4","article-title":"Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment","volume":"18","author":"Qu","year":"2019","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00536-6","article-title":"IMiDs new and old","volume":"14","author":"Yamshon","year":"2019","journal-title":"Curr Hematol Malignancy Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in b-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of b cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc Japan Academy Ser B"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation\u2013lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.2.408","article-title":"The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum","volume":"168","author":"Sampaio","year":"1993","journal-title":"J Infect Diseases"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(01)00147-0","article-title":"Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit m. leprae-induced TNF\u03b1 production in vitro","volume":"56","author":"Sampaio","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1016\/j.htct.2020.10.372","article-title":"MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Andorsky","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large b-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-73440-4_3","article-title":"\u201cPomalidomide\u201d","volume-title":"Resistance to Targeted Therapies in Multiple Myeloma. Resistance to Targeted Anti-Cancer Therapeutics","author":"Yeung","year":"2021"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","volume":"188","author":"Siegel","year":"2020","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1182\/blood-2021-146851","article-title":"Trial in progress: Pomalidomide plus rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory diffuse Large b-cell lymphoma (PRIDE)","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/cancers12092541","article-title":"Combination treatment with GSK126 and pomalidomide induces b-cell differentiation in EZH2 gain-of-Function mutant diffuse Large b-cell lymphoma","volume":"12","author":"Park","year":"2020","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e71754","DOI":"10.1371\/journal.pone.0071754","article-title":"Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1200\/JCO.2017.35.15_suppl.7516","article-title":"Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed\/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL)","volume":"35","author":"Tun","year":"2017","journal-title":"Am Soc Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1009091","DOI":"10.1371\/journal.ppat.1009091","article-title":"Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2","volume":"17","author":"Shrestha","year":"2021","journal-title":"PloS Pathogens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.3390\/cancers12092528","article-title":"Immunomodulatory drugs in acute myeloid leukemia treatment","volume":"12","author":"Piccolomo","year":"2020","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"New Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors ikaros and aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Ann Rheum Diseases"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood J Am Soc Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood J Am Soc Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.2.415","article-title":"Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma","volume":"64","author":"Drucker","year":"2003","journal-title":"Mol Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200410000-00013","article-title":"Combined effect of recombinant CD19\u00d7 CD16 diabody and thalidomide in a preclinical model of human b cell lymphoma","volume":"15","author":"Schlenzka","year":"2004","journal-title":"Anti Cancer Drugs"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/37018","article-title":"Thalidomide regulation of NF-\u03baB proteins limits tregs activity in chronic lymphocytic leukemia","volume":"23","author":"Sk\u00f3rka","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000988","article-title":"Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells","volume":"24","author":"Pointon","year":"2010","journal-title":"Oncol Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.22034\/APJCP.2017.18.11.3055","article-title":"Anti-vascular endothelial growth factor targeting by curcumin and thalidomide in acute myeloid leukemia cells","volume":"18","author":"Salemi","year":"2017","journal-title":"Asian Pacific J Cancer Prevention: APJCP"},{"key":"B50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/DDDT.S228610","article-title":"Curcumin combined with thalidomide reduces expression of STAT3 and bcl-xL, leading to apoptosis in acute myeloid leukemia cell lines","volume":"14","author":"Kian","year":"2020","journal-title":"Drug Design Dev Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.07.090","article-title":"Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via ras inactivation","volume":"374","author":"Noman","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3892\/ol_00000083","article-title":"Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute myelogenous leukemia cell line","volume":"1","author":"Girgis","year":"2010","journal-title":"Oncol Lett"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802588352","article-title":"Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1","volume":"50","author":"Liu","year":"2009","journal-title":"Leukemia Lymphoma"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-006-0036-9","article-title":"Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine","volume":"54","author":"Czy\u017cewski","year":"2006","journal-title":"Archivum Immunologiae Therapiae Experimentalis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500467891","article-title":"Ex vivo activity of thalidomide in childhood acute leukemia","volume":"47","author":"Styczynski","year":"2006","journal-title":"Leukemia Lymphoma"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple MyelomaLenalidomide in combination with checkpoint blockade in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"Van Der Veer","year":"2011","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell LymphomaAnti-lymphangiogenesis by lenalidomide in MCL","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood J Am Soc Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"35","author":"Qian","year":"2011","journal-title":"Leukemia Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant b cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.177","article-title":"Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas","volume":"28","author":"Sakamaki","year":"2014","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood.V112.11.2612.2612","article-title":"Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression","volume":"112","author":"Zhang","year":"2008","journal-title":"Am Soc Hematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"523842","DOI":"10.1155\/2012\/523842","article-title":"Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non-hodgkin\u2019s lymphomas","volume":"2012","author":"Gunnellini","year":"2012","journal-title":"Adv Hematol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-13-1569","article-title":"Antitumoral activity of lenalidomide in In vitro and In vivo models of mantle cell lymphoma involves the destabilization of cyclin D1\/p27KIP1 ComplexesLenalidomide targets cyclin D1\/p27KIP1 in MCL","volume":"20","author":"Moros","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21WAF1\/Cip1-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal b cells through a PI3-kinase\u2013dependent pathway","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood J Am Soc Hematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-447664","article-title":"Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment","volume":"121","author":"Schulz","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3324\/haematol.2014.113217","article-title":"Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia","volume":"100","author":"Fiorcari","year":"2015","journal-title":"Haematologica"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.exphem.2020.05.001","article-title":"Cyclosporine enhances the sensitivity to lenalidomide in MDS\/AML in vitro","volume":"86","author":"He","year":"2020","journal-title":"Exp Hematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-428573","article-title":"Lenalidomide-mediated enhanced translation of C\/EBP\u03b1-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia","volume":"121","author":"Hickey","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del (5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30585","article-title":"Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications","volume":"123","author":"Stahl","year":"2017","journal-title":"Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.296","article-title":"Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis","volume":"24","author":"Matsuoka","year":"2010","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood.V124.21.4.4","article-title":"Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with del (5q)","volume":"124","author":"Fink","year":"2014","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0645-3","article-title":"ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01798","article-title":"Synergistic antimyeloma activity of dendritic cells and pomalidomide in a murine myeloma model","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br J Haematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00977","article-title":"Immunomodulatory drugs exert anti-leukemia effects in acute myeloid leukemia by direct and immunostimulatory activities","volume":"9","author":"Le Roy","year":"2018","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"New Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.8851","article-title":"Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma","volume":"24","author":"Richardson","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"New Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial","volume":"31","author":"Rosi\u00f1ol","year":"2017","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06937.x","article-title":"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the cancer and leukemia group b","volume":"140","author":"Smith","year":"2008","journal-title":"Br J Haematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/blood.V104.11.3284.3284","article-title":"Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (Sll): CALGB study 50002","volume":"104","author":"Grinblatt","year":"2004","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.6583","article-title":"Durable remissions after rituximab plus thalidomide for relapsed\/refractory mantle cell lymphoma","volume":"22","author":"Drach","year":"2004","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer: Interdiscip Int J Am Cancer Society"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/10245330500276592","article-title":"A phase II study of thalidomide and vinblastine for palliative patients with hodgkin\u2019s lymphoma","volume":"11","author":"Kuruvilla","year":"2006","journal-title":"Hematology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01375.x","article-title":"The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant hodgkin\u2019s lymphoma","volume":"84","author":"Garc\u00eda-Sanz","year":"2010","journal-title":"Eur J Haematol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3892\/mco.2014.307","article-title":"Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non\u2212Hodgkin\u2019s lymphoma: A prospective study of 46 cases","volume":"2","author":"Wu","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2005.08.006","article-title":"Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma","volume":"18","author":"Oxberry","year":"2006","journal-title":"Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.98","article-title":"Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide\/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia","volume":"23","author":"Giannopoulos","year":"2009","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0669","article-title":"Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.635644","article-title":"Treating chronic lymphocytic leukemia with thalidomide and lenalidomide","volume":"12","author":"Giannopoulos","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.6640","article-title":"Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL","volume":"23","author":"Furman","year":"2005","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3324\/%25x","article-title":"Thalidomide induced remission of refractory diffuse large b-cell lymphoma post-allogeneic SCT","volume":"91","author":"Tueger","year":"2006","journal-title":"Haematologica"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2754","article-title":"Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)","volume":"38","author":"Kiesewetter","year":"2020","journal-title":"Hematol Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23789","article-title":"Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"113","author":"Raza","year":"2008","journal-title":"Cancer: Interdiscip Int J Am Cancer Society"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.834","article-title":"Efficacy and safety of thalidomide in patients with acute myeloid leukemia","volume":"99","author":"Steins","year":"2002","journal-title":"Blood J Am Soc Hematol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04639.x","article-title":"Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia","volume":"123","author":"Thomas","year":"2003","journal-title":"Br J Haematol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood J Am Soc Hematol"},{"key":"B116","article-title":"Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial","volume":"32","author":"Chung","year":"2012","journal-title":"Anticancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.07.003","article-title":"The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline","volume":"85","author":"Leitch","year":"2013","journal-title":"Crit Rev Oncology\/hematology."},{"key":"B118","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/10428194.2016.1190971","article-title":"Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)","volume":"58","author":"Kenealy","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"B119","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1182\/blood.V122.21.5172.5172","article-title":"Imatinib (IM) plus thalidomide (Thali), a effective combination for the treatment of chronic myeloid leukemia (CML) Philadelphia chromosomepositive (Ph+) in IM-resistant disease. Report of 14 new cases from a single center in Mexico","volume":"122","author":"Monroy","year":"2013","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"New Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"New Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"New Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in north America","volume":"357","author":"Weber","year":"2007","journal-title":"New Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.305","article-title":"Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del (5q) MDS","volume":"28","author":"List","year":"2014","journal-title":"Leukemia"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0725-0","article-title":"Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS","volume":"34","author":"Ossenkoppele","year":"2020","journal-title":"Leukemia"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for b-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138731","article-title":"Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma (MCL): 7-year analysis from a multi-center phase II study","volume":"136","author":"Yamshon","year":"2020","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular b-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers","year":"2020","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1313230","article-title":"Lenalidomide in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Itchaki","year":"2017","journal-title":"Expert Opin Investigational Drugs"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495341","article-title":"Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia","volume":"122","author":"Strati","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: comparing tafasitamab+ lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large b-cell lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"861060","DOI":"10.1155\/2012\/861060","article-title":"Lenalidomide in diffuse large b-cell lymphoma","volume":"2012","author":"Thieblemont","year":"2012","journal-title":"Adv Hematol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone b-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019phase II study of the French oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.8524","article-title":"Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases","volume":"27","author":"Dueck","year":"2009","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2712","article-title":"Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience","volume":"38","author":"Sakamoto","year":"2020","journal-title":"Hematol Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/hon.55_2879","article-title":"Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL)","volume":"39","author":"Ruan","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152678","article-title":"Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13","volume":"113","author":"Fehniger","year":"2009","journal-title":"Blood J Am Soc Hematol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/leu.2011.294","article-title":"Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia","volume":"26","author":"Pollyea","year":"2012","journal-title":"Leukemia"},{"key":"B153","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ajh.23746","article-title":"Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients","volume":"89","author":"Govindaraj","year":"2014","journal-title":"Am J Hematol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3324\/haematol.2012.076414","article-title":"Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia","volume":"98","author":"Pollyea","year":"2013","journal-title":"Haematologica"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.03.022","article-title":"Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis","volume":"38","author":"Buckstein","year":"2014","journal-title":"Leukemia Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/16078454.2019.1631425","article-title":"A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"24","author":"Kunacheewa","year":"2019","journal-title":"Hematology"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1369070","article-title":"A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML)\u2013AGMT_CMML-1","volume":"59","author":"Burgstaller","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Chanan-Khan","year":"2013","journal-title":"Blood Cancer J"},{"key":"B163","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/14737140.2014.906904","article-title":"Pomalidomide for the treatment of relapsed\u2013refractory multiple myeloma: a review of biological and clinical data","volume":"14","author":"Offidani","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"B164","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1182\/blood-2019-126192","article-title":"A phase Ia\/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed\/refractory CLL, DLBCL or other b-cell lymphomas","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"key":"B166","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2147\/TCRM.S69211","article-title":"Profile of pomalidomide and its potential in the treatment of myelofibrosis","volume":"11","author":"Gowin","year":"2015","journal-title":"Ther Clin Risk Management"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0693-4","article-title":"Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS","volume":"34","author":"Zeidner","year":"2020","journal-title":"Leukemia"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood.V126.23.1351.1351","article-title":"Immune modulation with pomalidomide after induction chemotherapy in newly diagnosed acute myeloid leukemia (AML)","volume":"126","author":"Montiel-Esparza","year":"2015","journal-title":"Blood"},{"key":"B169","article-title":"Thalidomide","volume-title":"StatPearls","author":"Grogan","year":"2022"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","first-page":"blood.2021014956","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.lrr.2022.100315","article-title":"Lenalidomide induced secondary acute lymphoblastic leukemia in a multiple myeloma patient: A case-report","volume":"17","author":"Khan","year":"2022","journal-title":"Leukemia Res Rep"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"science"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and a iolos via modulation of the e 3 ubiquitin ligase complex CRL 4 CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm1547","article-title":"Function and regulation of cullin\u2013RING ubiquitin ligases","volume":"6","author":"Petroski","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/nature05175","article-title":"Molecular architecture and assembly of the DDB1\u2013CUL4A ubiquitin ligase machinery","volume":"443","author":"Angers","year":"2006","journal-title":"Nature"},{"key":"B179","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ddtec.2019.02.004","article-title":"Cereblon modulators: Low molecular weight inducers of protein degradation","volume":"31","author":"Chamberlain","year":"2019","journal-title":"Drug Discovery Today: Technologies"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20160762","article-title":"Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway","volume":"474","author":"Collins","year":"2017","journal-title":"Biochem J"},{"key":"B181","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e941742","DOI":"10.4161\/21624011.2014.941742","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Kr\u00f6nke","year":"2014","journal-title":"Oncoimmunology"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.LBA-5.LBA-5","article-title":"Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1021\/jm9603328","article-title":"Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity","volume":"39","author":"Muller","year":"1996","journal-title":"J Medicinal Chem"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del (5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"B188","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/9781681083674118030005","article-title":"Role of immunomodulatory drugs in the treatment of lymphoid and myeloid malignancies","volume":"3","author":"Fuchs","year":"2018","journal-title":"Front Clin Drug Res Hematol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate ikaros and aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leukemia Res"},{"key":"B191","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated b-cell-like subtype diffuse large b-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs","volume":"12","author":"D\u2019Souza","year":"2021","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of b-cell lymphoma pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic b-cell population in the interfollicular zone","volume":"91","author":"Dogan","year":"1998","journal-title":"Blood J Am Soc Hematol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08152.x","article-title":"Monocytes\/macrophages but not T lymphocytes are the major targets of the CCL3\/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells","volume":"150","author":"Zucchetto","year":"2010","journal-title":"Br J Haematol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia b cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in b cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7020736","article-title":"Lymphoma: immune evasion strategies","volume":"7","author":"Upadhyay","year":"2015","journal-title":"Cancers"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800570","article-title":"Activation of Th1 immunity within the tumor microenvironment is associated with clinical response to lenalidomide in chronic lymphocytic leukemia","volume":"201","author":"Aue","year":"2018","journal-title":"J Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003774","article-title":"Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma","volume":"5","author":"M\u00e9nard","year":"2021","journal-title":"Blood Advances"},{"key":"B203","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.3324\/haematol.2017.178947","article-title":"Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance","volume":"103","author":"Danhof","year":"2018","journal-title":"Haematologica"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+ Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J Immunother"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2022.05.012","article-title":"Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating notch signaling","volume":"29","author":"Geng","year":"2022","journal-title":"Cell Chem Biol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Ot\u00e1hal","year":"2016","journal-title":"Oncoimmunology"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Research: an Off J Am Assoc Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/Lenalidomide in Relapsed\/Refractory non-hodgkin\u2019s lymphoma: A phase I California cancer consortium study of safety, efficacy and immune correlative analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000218","article-title":"CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells","volume":"8","author":"Martens","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B212","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1200\/jco.2015.33.15_suppl.8588","article-title":"Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide","volume":"33","author":"Boxhammer","year":"2015","journal-title":"Am Soc Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.624661","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"10","author":"Offidani","year":"2021","journal-title":"Front Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2019-123483","article-title":"Four-year follow-up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM)","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0809-x","article-title":"Immunomodulatory drugs activate NK cells via both zap-70 and cereblon-dependent pathways","volume":"35","author":"Hideshima","year":"2021","journal-title":"Leukemia"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005400","article-title":"An autologous culture model of nodal b-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies","volume":"5","author":"Roider","year":"2021","journal-title":"Blood Advances"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01216-w","article-title":"Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"265840","DOI":"10.1155\/2014\/265840","article-title":"Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells","volume":"2014","author":"Acebes-Huerta","year":"2014","journal-title":"BioMed Res Int"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0555","article-title":"The IKZF1-IRF4\/IRF5 axis controls polarization of myeloma-associated macrophages","volume":"9","author":"Mougiakakos","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B224","doi-asserted-by":"publisher","first-page":"eabl9171","DOI":"10.1126\/sciadv.abl9171","article-title":"Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy","volume":"8","author":"Cao","year":"2022","journal-title":"Sci Adv"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0114-0","article-title":"Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin d pathway","volume":"32","author":"Busch","year":"2018","journal-title":"Leukemia"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e1428158","DOI":"10.1080\/2162402X.2018.1428158","article-title":"Obinutuzumab activates Fc\u03b3RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)","volume":"7","author":"Elias","year":"2018","journal-title":"Oncoimmunology"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635173","article-title":"Harnessing and enhancing macrophage phagocytosis for cancer therapy","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12087","article-title":"Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs\u00ae immunomodulatory compounds lenalidomide and pomalidomide","volume":"139","author":"Henry","year":"2013","journal-title":"Immunology"},{"key":"B230","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ejh.13065","article-title":"Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients","volume":"101","author":"Palma","year":"2018","journal-title":"Eur J Haematol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02411-y","article-title":"Lenalidomide improves the therapeutic effect of an interferon-\u03b1-dendritic cell-based lymphoma vaccine","volume":"68","author":"Lapenta","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01370","article-title":"Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V116.21.492.492","article-title":"Lenalidomide decreases PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma\/dendritic cell fusion vaccine in vitro","volume":"116","author":"Luptakova","year":"2010","journal-title":"Blood"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T Cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"8941260","DOI":"10.1155\/2016\/8941260","article-title":"Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response","volume":"2016","author":"Reiser","year":"2016","journal-title":"J Immunol Res"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.11.003","article-title":"Tumor microenvironment (TME)-driven immune suppression in b cell malignancy","volume":"1863","author":"Nicholas","year":"2016","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"key":"B239","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"B242","doi-asserted-by":"publisher","first-page":"513702","DOI":"10.1155\/2012\/513702","article-title":"Molecular action of lenalidomide in lymphocytes and hematologic malignancies","volume":"2012","author":"McDaniel","year":"2012","journal-title":"Adv Hematol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"key":"B244","doi-asserted-by":"publisher","first-page":"20476","DOI":"10.18632\/oncotarget.24944","article-title":"Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation","volume":"9","author":"Fostier","year":"2018","journal-title":"Oncotarget"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006073","article-title":"Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1\/PD-1 immunotherapy","volume":"137","author":"Ioannou","year":"2021","journal-title":"Blood"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03171","article-title":"Immunomodulatory drugs in the context of autologous hematopoietic stem cell transplantation associate with reduced pro-tumor T cell subsets in multiple myeloma","volume":"9","author":"Di Lullo","year":"2019","journal-title":"Front Immunol"},{"key":"B247","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-Cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action. seminars in hematology","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-021-02120-z","article-title":"Unleashing the power of NK cells in anticancer immunotherapy","volume":"100","author":"Vogler","year":"2022","journal-title":"J Mol Med"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2005.25.604","article-title":"Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-\u03b8 activation and enhancing the DNA-binding activity of AP-1 but not NF-\u03baB, OCT-1, or NF-AT","volume":"25","author":"Payvandi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2963.2963","article-title":"CC-122 is a novel pleiotropic pathway modifier with potent in vitro immunomodulatory and anti-angiogenic properties and in vivo anti-tumor activity in hematological cancers","volume":"120","author":"Gandhi","year":"2012","journal-title":"Blood"},{"key":"B255","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2019002395","article-title":"Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier","volume":"135","author":"Carpio","year":"2020","journal-title":"Blood"},{"key":"B256","doi-asserted-by":"publisher","first-page":"e1231290","DOI":"10.1080\/2162402X.2016.1231290","article-title":"CC-122 immunomodulatory effects in refractory patients with diffuse large b-cell lymphoma","volume":"5","author":"Cubillos-Zapata","year":"2016","journal-title":"Oncoimmunology"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B258","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-021-00252-z","article-title":"Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies","volume":"10","author":"Zhu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B260","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001341","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular cytotoxicity of next-generation CD20 monoclonal AntibodiesCellular cytotoxicity of CD20 monoclonal antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with b-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"key":"B265","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03176","article-title":"Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy","volume":"9","author":"Patente","year":"2019","journal-title":"Front Immunol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001410","article-title":"Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses","volume":"4","author":"Phan","year":"2020","journal-title":"Blood Adv"},{"key":"B268","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/cancers13112542","article-title":"Bone marrow mesenchymal stromal cells in multiple myeloma: Their role as active contributors to myeloma progression","volume":"13","author":"Maiso","year":"2021","journal-title":"Cancers"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmt142","article-title":"Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma","volume":"46","author":"Chang","year":"2014","journal-title":"Acta Biochim Biophys Sinica"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-424630","article-title":"Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.06.004","article-title":"Impact of lenalidomide on the functional properties of human mesenchymal stromal cells","volume":"40","author":"Wobus","year":"2012","journal-title":"Exp Hematol"},{"key":"B272","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/ijms19072031","article-title":"New insights in anti-angiogenesis in multiple myeloma","volume":"19","author":"Ribatti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.591741","article-title":"Angiogenesis in lymph nodes is a critical regulator of immune response and lymphoma growth","volume":"11","author":"Menzel","year":"2020","journal-title":"Front Immunol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170601074646","article-title":"A mini-review on thalidomide: Chemistry, mechanisms of action, therapeutic potential and anti-angiogenic properties in multiple myeloma","volume":"24","author":"Mercurio","year":"2017","journal-title":"Curr Medicinal Chem"},{"key":"B276","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"B277","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.exphem.2013.10.007","article-title":"Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia","volume":"42","author":"Maffei","year":"2014","journal-title":"Exp Hematol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001955","article-title":"Lenalidomide\/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study","volume":"4","author":"Delfau-Larue","year":"2020","journal-title":"Blood Adv"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013526","article-title":"Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study","volume":"139","author":"Bachy","year":"2022","journal-title":"Blood"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2476","article-title":"Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: Correlation between responses and immune characteristics","volume":"22","author":"Vitale","year":"2016","journal-title":"Clin Cancer Research: an Off J Am Assoc Cancer Res"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"B285","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21037\/tcr.2017.01.08","article-title":"The role of novel immunotherapies in non-Hodgkin lymphoma","volume":"6","author":"Pishko","year":"2017","journal-title":"Trans Cancer Res"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T Cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B287","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann Trans Med"},{"key":"B288","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxac013","article-title":"A variety of \u2018exhausted\u2019 T cells in the tumor microenvironment","author":"Nagasaki","year":"2022","journal-title":"Int Immunol"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129206","article-title":"Immunotherapy of lymphomas","volume":"130","author":"Ansell","year":"2020","journal-title":"J Clin Invest"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Research: an Off J Am Assoc Cancer Res"},{"key":"B292","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1182\/blood.V126.23.506.506","article-title":"A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with Relapsed\/Refractory multiple myeloma (RRMM)","volume":"126","author":"Badros","year":"2015","journal-title":"Blood"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for Relapsed\/Refractory multiple myeloma (RRMM): Keynote-023","volume":"126","author":"San Miguel","year":"2015","journal-title":"Blood"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br J Haematol"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B298","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B299","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of car T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"B300","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"Pan","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136279","article-title":"Lenalidomide enhance CAR T-cells response in patients with Refractory\/Relapsed Large b cell lymphoma experiencing progression after infusion","volume":"136","author":"Thieblemont","year":"2020","journal-title":"Blood"},{"key":"B302","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1182\/blood-2019-126369","article-title":"A phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory Large b-cell lymphoma (ZUMA-14)","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"B303","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood-2021-151109","article-title":"Lenalidomide exposure at time of CAR T-cells expansion enhances response of Refractory\/Relapsed aggressive Large b-cell lymphomas","volume":"138","author":"Lemoine","year":"2021","journal-title":"Blood"},{"key":"B304","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: A case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B305","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.3390\/cancers13194867","article-title":"Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of lenalidomide to r-CHOP improves outcomes in newly diagnosed diffuse Large b-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.013","article-title":"A cereblon modulator CC-885 induces CRBN- and p97-dependent PLK1 degradation and synergizes with volasertib to suppress lung cancer","volume":"18","author":"Li","year":"2020","journal-title":"Mol Ther - Oncolytics"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1153","article-title":"Pomalidomide alters pancreatic macrophage populations to generate an immune-responsive environment at precancerous and cancerous lesions","volume":"79","author":"Bastea","year":"2019","journal-title":"Cancer Res"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-011-0670-5","article-title":"The immunomodulatory drug lenalidomide restores a vitamin d sensitive phenotype to the vitamin d resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics","volume":"17","author":"Brosseau","year":"2012","journal-title":"Apoptosis"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009335001","article-title":"Phase I study of oral lenalidomide in patients with refractory metastatic cancer","volume":"49","author":"Dahut","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"B311","doi-asserted-by":"publisher","first-page":"e26494","DOI":"10.4161\/onci.26494","article-title":"Trial watch: Lenalidomide-based immunochemotherapy","volume":"2","author":"Semeraro","year":"2013","journal-title":"Oncoimmunology"},{"key":"B312","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.3324\/haematol.2019.217943","article-title":"IKZF1\/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma","volume":"105","author":"Barrio","year":"2020","journal-title":"Haematologica"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2124694","article-title":"Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma","volume":"27","author":"Zuo","year":"2022","journal-title":"Hematology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017990\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T05:47:35Z","timestamp":1665553655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017990\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":313,"alternative-id":["10.3389\/fimmu.2022.1017990"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1017990","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"article-number":"1017990"}}